359 related articles for article (PubMed ID: 24961493)
1. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.
Komajda M; Böhm M; Borer JS; Ford I; Robertson M; Manolis AJ; Tavazzi L; Swedberg K;
Eur J Heart Fail; 2014 Jul; 16(7):810-6. PubMed ID: 24961493
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
[TBL] [Abstract][Full Text] [Related]
3. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
Böhm M; Robertson M; Borer J; Ford I; Komajda M; Mahfoud F; Ewen S; Swedberg K; Tavazzi L
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873681
[TBL] [Abstract][Full Text] [Related]
4. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
[TBL] [Abstract][Full Text] [Related]
5. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
6. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
[TBL] [Abstract][Full Text] [Related]
7. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
[TBL] [Abstract][Full Text] [Related]
9. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Robertson M; Ford I;
Int J Cardiol; 2013 Dec; 170(2):182-8. PubMed ID: 24225201
[TBL] [Abstract][Full Text] [Related]
10. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
[No Abstract] [Full Text] [Related]
12. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial.
Montero-Perez-Barquero M; Flather M; Roughton M; Coats A; Böhm M; Van Veldhuisen DJ; Babalis D; Solal AC; Manzano L
Eur J Heart Fail; 2014 Sep; 16(9):1009-15. PubMed ID: 25044535
[TBL] [Abstract][Full Text] [Related]
13. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT.
Komajda M; Tavazzi L; Swedberg K; Böhm M; Borer JS; Moyne A; Ford I;
Eur J Heart Fail; 2016 Sep; 18(9):1182-9. PubMed ID: 27210035
[TBL] [Abstract][Full Text] [Related]
14. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
Borer JS; Deedwania PC; Kim JB; Böhm M
Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
[TBL] [Abstract][Full Text] [Related]
15. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT.
Voors AA; van Veldhuisen DJ; Robertson M; Ford I; Borer JS; Böhm M; Komajda M; Swedberg K; Tavazzi L;
Eur J Heart Fail; 2014 Apr; 16(4):426-34. PubMed ID: 24504937
[TBL] [Abstract][Full Text] [Related]
16. Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative.
Ferreira JP; Duarte K; Pfeffer MA; McMurray JJV; Pitt B; Dickstein K; Zannad F; Rossignol P;
Eur J Heart Fail; 2018 Feb; 20(2):323-331. PubMed ID: 29314455
[TBL] [Abstract][Full Text] [Related]
17. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.
Komajda M; Böhm M; Borer J; Ford I; Krum H; Tase A; Tavazzi L; Swedberg K
Eur J Heart Fail; 2013 Jan; 15(1):79-84. PubMed ID: 22892123
[TBL] [Abstract][Full Text] [Related]
18. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
Ekman I; Chassany O; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L; Swedberg K
Eur Heart J; 2011 Oct; 32(19):2395-404. PubMed ID: 21875859
[TBL] [Abstract][Full Text] [Related]
19. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.
Böhm M; Lloyd SM; Ford I; Borer JS; Ewen S; Laufs U; Mahfoud F; Lopez-Sendon J; Ponikowski P; Tavazzi L; Swedberg K; Komajda M
Eur J Heart Fail; 2016 Jun; 18(6):672-83. PubMed ID: 26952245
[TBL] [Abstract][Full Text] [Related]
20. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
